A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity

By Miki Okada-Iwabu, Toshimasa Yamauchi, Masato Iwabu, T. Honma, Ken-ichi Hamagami, K. Matsuda, Mamiko Yamaguchi, H. Tanabe, T. Kimura-Someya, M. Shirouzu and 7 more. Nature, 2013

708 citations recorded by the source corpus.

Subfields: Endocrine and Autonomic Systems, Epidemiology, Physiology

View Paper: https://www.semanticscholar.org/paper/8d066c1e534bfd21299e87d8d1fc65a298b3a294

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrine and Autonomic Systems

1. H. Fang
2. R. L. Judd
3. Haiming Cao
4. G. Hotamışlıgil

In Epidemiology

1. B. Spiegelman
2. E. Rosen
3. H. Fang
4. R. L. Judd
5. G. Hotamışlıgil
6. Haiming Cao
7. Richard J. Johnson
8. Y. Sautin

In Physiology

1. B. Spiegelman
2. E. Rosen
3. H. Fang
4. R. L. Judd
5. G. Hotamışlıgil
6. Haiming Cao
7. P. Seale
8. S. Kajimura

Citations in the corpus

• What We Talk About When We Talk About Fat (2014, positive): “Finally, small molecule activators of the ADIPOR1/R2 receptors might be of significant utility (Okada-Iwabu et al., 2013).”
• GENeration (2015, neutral): “Once the "front-end" concept was working, the remaining conversion effort, to get all of NASTRAN on a "4G" computer, while involving significant volumes of code, would not require the further system type extensions.”
• Adiponectin Regulation and Function (2018, positive): “These properties have made adiponectin and its receptors targets for drug discovery and development (225).”